Overview
Status
Active
Registry date
2023-07-05
Share capital
100,000.00 PLN
Registered address
ul. Juliana Ursyna Niemcewicza 17/11, 02-306 Warszawa, Poland
Electronic delivery address
AE:PL-80773-95719-UFUCH-19
Financials
Revenue history
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 2 of 2 financial statements were filed late (the longest delay 680 days for 2023).
- 2025not filed
- 202427/05/2026
- 202326/05/2026
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Industry
Authorized Representatives
Andrei Senatov – Management Board Member
Venelin Georgiev – Management Board Member
Stanislav Zaverzaiev – Attorney-in-fact
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Venelin Georgievage 57 | 80 | $21,609.94 | 80% |
Andrei Senatovage 52 | 20 | $5,402.49 | 20% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2023-07-23.
93 1020 1013 0000 0402 0502 6218
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
FAQ
The main business activity of Pharmline Company focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on July 5, 2023.
The headquarters is located at: ul. Juliana Ursyna Niemcewicza 17, 02-306 Warszawa.
The share capital of the company is PLN 100,000 (approx. $27,012).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
No, the company recorded a net loss of $157,736 in 2024. For comparison, in 2023 the loss was $24,769, meaning the company increased its loss by 504.8%.
The largest operating cost category falls under external services. This category amounted to $64,047 in 2024, representing 41% of all operating expenses.
Last updated: 2026-07-14